G protein-coupled receptors as targets for drug design

Biotecnologia Aplicada

Volumn 26, Issue 1, 2009, Pages 24-33

  Veulens, Ania De La Nuez ^a   Rodríguez, Rolando ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

7TM; Docking; Drug design; GPCR; Molecular modeling; Receptor; Virtual screening

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; APELIN; DOVAN; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; FAMOTIDINE; FENTANYL; FEXOFENADINE; G PROTEIN COUPLED RECEPTOR; GABAPENTIN; GHRELIN; HISTAMINE; IMITEX; LEUPRORELIN; LORATADINE; LOSARTAN; LOSARTAN POTASSIUM; MELANIN CONCENTRATING HORMONE; NEUROMEDIN U; NOCICEPTIN; OLANZAPINE; ONDANSETRON; OREXIN; PROLACTIN RELEASING FACTOR; RANITIDINE; RELAXIN; RISPERIDONE; SALMETEROL; SALMETEROL XINAFOATE; SUCCINIC ACID; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II; VALSARTAN;

ALLERGY; ASTHMA; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HYPERTENSION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MIGRAINE; NONHUMAN; PAIN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; ULCER; VOMITING;

EID: 72049126087     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90-113. (Pubitemid 32260396)
2. Oliveira LPA, Vriend G. A common motif in G-protein-coupled seven transmembrane helix receptors. J Comput Aided Mol Des 1993;7:649-658
3. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289:739-745 (Pubitemid 30650186)
4. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 2004;343:1409-1438 (Pubitemid 39387834)
5. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potencial for drug discovery. Nat Rev Drug Discov 2002;1:808-820
6. Klabunde T, Hessler G. Drug Design Strategies for Targeting G-Protein-Coupled Receptors. ChemBioChem 2002;3:928-944 (Pubitemid 35189597)
7. Farrens DL, Altenbach C, Yang K, Hubell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996;274:768-770 (Pubitemid 26398253)
8. Dunham TD, Farrens DL. Conformational changes in Rhodopsin. J Biol Chem 1999;274:1683-1690
9. Jensen AD, Guarnieri F, Rasmussen SGF, Asmar F, BallesterosJA, Gether U. Agonist-induced conformational changes at the cytoplasmatic side of transmembrane segment 6 in the B2- adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001;276:9279-9290 (Pubitemid 37385512)
10. Okamoto T, Murayama Y, Hayashi Y, Inagaki M, Ogata E, Nishimoto I. Identification of a Gs activator region of the beta 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell 1991;67:723-730 (Pubitemid 121001485)
11. Heldin CH. Dimerization of cell surface receptors in signaltransduction. Cell 1995;80:213-223
12. Fukushima Y, Asano T, Saitoh T, Anai M, Funaki M, Ogihara T, et al. Oligomer formation of histamine H2 receptors expressed in Sf9 and COS7 cells. FEBS Lett 1997;409:283-286 (Pubitemid 27273893)
13. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a α2-adrenergicreceptor transmembrane domain inhibits both receptordimerization and activation. J Biol Chem 1996;271:16384-16392 (Pubitemid 26236264)
14. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. Detection of α2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000;97:3684-3689 (Pubitemid 30183363)
15. AbdAlla S, Lother H, Abdel-Tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001;276:39721-39726
16. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. ProcNatl Acad Sci USA 2000;97:8606-8611 (Pubitemid 30639720)
17. Auld DS, Diller D, Ho KK. Targeting signal transduction with large combinatorial collections. Drug Discov Today 2002;7:1206-1213 (Pubitemid 35472037)
18. Evers A, Hessler G, Matter H, Klabunde T. Virtual Screening of Biogenic Amine-Binding G-Protein Coupled Receptors: Comparative Evaluation of Protein- and Ligand-Based Virtual Screening Protocols. J Med Chem 2005;48:5448-5465 (Pubitemid 41209243)
19. Howard A, McAllister G, Feighner S, Liu Q, Nargund R, Van de Ploeg L, Patchett A. Orphan G protein-coupled receptors and natural ligand discovery. Trends in Pharmacol Sci 2001;22:132-140 (Pubitemid 32181844)
20. Drews J. Drug discovery: A historical perspective. Science 2000;287:1960-1964
21. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-246 . (Pubitemid 34143072)
22. Beaumont K, Schmid E, Smith DA. Oral delivery of G protein-coupled receptor modulators: An explanation for observed class diference. Bioorg Med Chem Lett 2005;15:3658-3664 (Pubitemid 41038955)
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26. (Pubitemid 33653411)
24. Freidinger RM. Nonpeptidic ligands for peptide and protein receptors. Curr Opin Chem Biol 1999;3:395-406. (Pubitemid 29376101)
25. Beeley NRA. Can peptides be mimicked?. Drug Discov Today 2000; 5: 354-363
26. Gurrath M. Peptide-binding G protein-coupled receptors: New. opportunities for drug design. Curr Med Chem 2001;8:1605-1648 (Pubitemid 33076805)
27. Veber DF. Design and discovery in the development of peptide analogues. In: Smith JA, Rivier JE, editors. Peptides, Chemistry, and Biology. Proceedings of the 12th American Peptide Symposium; 1992; ESCOM, Leiden, Netherlands.
28. Alfaro-López J, Okayama T, Hosohata K, Davis P, Porreca F, Yamamura HI, Hruby VJ. Exploring the structure-activity relationships of [1-(4-tert-butyl-3′-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand. J Med Chem 1999;42:5359-5368 (Pubitemid 30036771)
29. Alexopoulos K, Panagiotopoulos D, Mavromoustakos T, Fatseas P, Paredes-Carbajal MC, Mascher D, et al. Design, synthesis, and modeling of novel cyclic thrombin receptor-derived peptide analogues of the Ser42-Phe-Leu-Leu- Arg46 motif sequence with fixed conformations of pharmacophoric groups: importance of a Phe/Arg/NH2 cluster for receptor activation and implications in the design of nonpeptide thrombin receptor mimetics. J Med Chem 2001;44:328-339 (Pubitemid 32114166)
30. Huang P, Loew GH, Funamizu H, Mimura M, Ishiyama N, Hayashida M, et al. Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. J Med Chem 2001;44:4082-4091 (Pubitemid 33095317)
31. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002;45:1799-1805 (Pubitemid 34415375)
32. Cramer RD, Patterson DE, Bunce JD. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J Am Chem Soc 1988;110:5959-5967
33. Kim KH, Greco G, Novellino EA. Critical Review of Recent CoMFA Applications. Perspect Drug Discov Des 1998;12-14:257-315. (Pubitemid 128488935)
34. Lanig H, Utz W, Gmeiner P. Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1- ylmethyl] pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1- ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem 2001;44:1151-1157
35. Hoffman B, Cho SJ, Zheng W, Wyrick S, Nichols DE, Mailman RB, Tropsha A. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J Med Chem 1999;42:3217-3226
36. McGaughey GB, Mewshaw RE. Application of comparative molecular field analysis to dopamine D2 partial agonists. Bioorg Med Chem 1999;7:2453-2456 (Pubitemid 30122746)
37. Gaillard P, Carrupt PA, Testa B,Schambel P. Binding of arylpiperazines, (aryloxy) propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. J Med Chem 1996;39:126-134 (Pubitemid 126590452)
38. López-Rodríguez ML, Benhamu B, Viso A, Morcillo MJ, Murcia M, Orensanz L, Alfaro MJ, Martin MI. Benzimidazole derivatives. Part 1: Synthesis and structure-activity relationships of new benzimidazole-4- carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists. Bioorg Med Chem 1999;7:2271-2281
39. López-Rodríguez ML, Murcia M, Benhamu B, Viso A, Campillo M, Pardo L. 3-D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT(4) receptor. Bioorg Med Chem Lett 2001;11:2807-2811
40. Chen Q, Wu CD, Maxwell D, Krudy GA, Dixon RAF, You TJ. A 3D QSAR analysis of in vitro binding affinity and selectivity of 3- isoxazolylsulfonylaminothiophenes as endothelin receptor antagonists. Quant Struct-Act Relat 1999;18:124-133
41. Siddiqi SM, Pearlstein RA, Sanders LH, Jacobson KA. Comparative molecular field analysis of selective A3 adenosine receptor agonists. Bioorg Med Chem 1995;3:1331-1343
42. Rieger JM, Brown ML, Sullivan GW, Linden J, Macdonald TL. Design, synthesis, and evaluation of novel adenosine A2A receptor agonists. J Med Chem 2001; 44: 531-539 (Pubitemid 32156095)
43. López-Rodríguez ML, Rosado ML, Benhamu B, Morcillo MJ, Fernández E, Schaper KJ. Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relation ships of hydan-toinphenylpiperazine derivatives with affinity for 5-HT1A and alpha 1 receptors. A comparison of CoMFA models. J Med Chem 1997;40: 1648-1656
44. Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin an-tagonists. J Med Chem 1988;31:2235-2246
45. Patchett AA, Nargund RP. Privileged structures -an update. Annu Rep Med Chem 2000; 35:289-298
46. Palucki BL, Feighner SD, Pong S-S, McKee KK, Hreniuk DL, Tan C, et al. Spiro(indoline-3,40 -piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg Med Chem Lett 2001;11:1955-1957 (Pubitemid 32675326)
47. Evans B, Pipe A, Clark L, Banks M. Identification of a potent and selective oxytocin antagonist, from screening a fully encoded differential release combinatorial chemical library. Bioorg Med Chem Lett 2001;11: 1297-1300 (Pubitemid 32434356)
48. Lattman E, Billington DC, Poyner DR, Arayarat P, Howitt SB,Lawrence S, Offel M. Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor. Drug Des Discov 2002;18:9-21. (Pubitemid 36329304)
49. Cha MY, Choi BC, Kang KH, Pae AN, Choi KI, Cho YS, et al. Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands. Bioorg Med Chem Lett 2002;12:1327-1330
50. González-Gómez JC, Santana L, Uriarte E, Brea J, Villazon M, Loza MI, et al. New aryl-piperazine derivatives with high afinity for a1A, D2, and 5-HT2A receptors. Bioorg Med Chem Lett 2003;13:175-178
51. Pebay-Peyroula E, Rummel G, Rosenbusch JP, Landau EM. X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. Science 1997; 277:1676-1681 (Pubitemid 27446232)
52. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001;60:1-19. (Pubitemid 32595228)
53. Strahs D, Weinstein H. Comparative modeling and molecular dynamics studies of the delta, kappa and mu opioid receptors. Protein Eng 1997;10:1019-1038 (Pubitemid 28004648)
54. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271:24029-24035
55. Becker OM, Shacham S, Marantz Y, Noiman S. Modeling the 3Dstructure of GPCRs: advances and application to drug discovery. Curr Opin Drug Discov Dev 2003;6:353-361 (Pubitemid 36702308)
56. Shacham S, Topf M, Avisar N, Glaser F, Marantz Y, Bar-Haim S, et al. Modeling the 3D structure ofGPCRs from sequence. Med Res Rev 2001;21:472-483
57. Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Curr Opin Chem Biol 2002;6:439-446 (Pubitemid 34808727)
58. Shacham S, Marantz Y, Bar-Haim S, Kalid O, Warshaviak D, Avisar N, et al. PREDICT Modeling and In-Silico Screening for G-Protein Coupled Receptors. Proteins 2004;57:51-86.
59. Zhang Y, DeVries ME, Skolnick J. Structure modeling of all identified G protein-coupled receptors in the human genome. PLoS Comput Biol 2006;2:88-99.
60. Becker OM, Marantz Y, Shacham S, Inbal B, Heifetz A, Kalid O, Bar-Haim S, Warshaviak D, Fichman M, Noiman S. G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci USA 2004;101:11304-11309
61. Sale K, Faulon JL, Gray GA, Schoeniger JS, Young MM. Optimalbundling of transmembrane helices using sparse distance constraints. Prot Sci 2004;13:2613-2627 (Pubitemid 39274630)
62. Shi L, Javitch JA. The binding site of aminergic G protein- coupledreceptors: The transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 2002;42:437-467 (Pubitemid 34162546)
63. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, et al. Structural basis of glutamate recognition by a dimeric metabotropicglutamate receptor. Nature 2000;407:971-977 (Pubitemid 30828061)
64. Du P, Salon JA, Tamm JA, Hou C, Cui W, Walker MW, et al. Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites. Prot Eng 1997;10:109-117 (Pubitemid 27113273)
65. Yang X, Wang Z, Dong W, Ling L, Yang H, Chen R. Modeling and docking of the three-dimensional structure of the human melanocortin 4 receptor. J Protein Chem 2003;22:335-344 (Pubitemid 37087794)
66. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, et al. III. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA 2002;99:12622-12627
67. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets?. Proteins 2003;50:5-25.
68. Evers A, Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem 2004;47:5381-5392 (Pubitemid 39382788)
69. Evers A, Klabunde T . Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem 2005;48:1088-1097 (Pubitemid 40270452)
70. Varady J, Wu X, Fang X, Min J, Hu Z, Levant B, et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J Med Chem 2003;46:4377-4392
71. Hamm HE. The Many Faces of G Protein Signaling. J Biol Chem 1998;273:669-672
72. Ji TH, Grossmann M, Ji I. G Protein-coupled Receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 1998;273:17299-17302
73. Civelli O, Nothacker HP, Saito Y, Wang Z, Lin SH, Reinscheid RK. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors. Trends Neurosci 2001;24:230-237 (Pubitemid 32204380)
74. Im D-S. Orphan G Protein-Coupled Receptors and Beyond. Jpn. J. Pharmacol 2002;90:101-106
75. Libert F, Vassart G, Parmentier M . Current developments in G-protein-coupled receptors. Curr Opin Cell Biol 1991;3:218-223
76. Fargin A, Raymond JR, Lohse MJ, Kobilka BK, Caron MG, Lefkowitz R. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 1988;335:358-360 (Pubitemid 18227219)
77. Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988;336:783-787 (Pubitemid 19014439)
78. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann Med 2004;36:204-214 (Pubitemid 38680197)
79. Civelli O. Functional genomics: the search for novel neurotransmitters and neuropeptides. FEBS Lett 1998;430:55-58 (Pubitemid 28307031)
80. Broach JR,Thorner J. High-throughput screening for drug discovery. Nature 1996;384:14-16
81. Brown AJ, Dyos SL, Whiteway MS, White JH, Watson MA, Marzioch M, et al. Functional coupling of mammalianreceptors to the yeast mating pathway using novel yeast/mammalian G protein alpha-subunit chimeras. Yeast 2000;16:11-22. (Pubitemid 30066092)
82. Maenhaut C, Van Sande J, Libert F, Abramowicz M, Parmentier M, Vanderhaegen JJ, et al. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun 1990; 173: 1169-1178
83. Libert F, Schiffmann SN, Lefort A, Parmentier M, Gerard C, Dumont JE, et al. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J 1991;10:1677-1682 (Pubitemid 21905634)
84. Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y, Damron DS. Sphingosylphosphorylcholine is a ligand for ovarian cancer G protein-coupled receptor 1. Nat Cell Biol 2000;2:261-267 (Pubitemid 30781110)
85. Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR. Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol 2001;153:429-434 (Pubitemid 34280225)
86. Kabarowski JHS, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001;293:702-705 (Pubitemid 32728673)
87. Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JHS, et al. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem 2001;276:41325-41335 (Pubitemid 37373292)
88. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55:1101-1107 (Pubitemid 29252378)
89. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000;275:36781-36786 (Pubitemid 32002087)
90. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997;387:620-624 (Pubitemid 27248768)
91. Gouldson PR, Kidley NJ, Bywater RP, Psaroudakis G, Brooks HD, Diaz C, et al. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor. Proteins 2004;56:67-84. (Pubitemid 38720839)
92. Bock JR, Gough DA. Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors. J Chem Inf Model 2005;45:1402-1414 (Pubitemid 41476023)
93. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera - A Visualization System for Exploratory Research and Analysis. J Comput Chem 2004;25:1605-1612
94. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377:532-535
95. Sutcliffe JG, de Lecea L . The hypocretins: setting the arousal threshold. Nat Rev Neurosci 2002;3:339-349
96. Smart D, Haynes AC, Williams G, Arch JR. Orexins and the treatment of obesity. Eur J Pharmacol 2002;440:199-212.
97. Lin SH, Arai AC, Espana RA, Berridge CW, Leslie FM, Huguenard JR, et al. Prolactin-releasing peptide (PrRP) promotes awakening and suppresses absence seizures. Neuroscience 2002;114:229-238
98. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and charaterization of a novel endogenous peptide ligand for thehuman APJ receptor. Biochem Biophys Res Commun 1998;251:471-476 (Pubitemid 28505047)
99. Hosoda H, Kojima M, Kangawa K. Ghrelin and the regulation of food intake and energy balance. Mol Interv 2002;2:494-503.
100. Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E . Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002;440:235-254 (Pubitemid 34458027)
101. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O . Molecular characterization of the melanin-concentrating-hormone receptor. Nature 1999;400:265-269
102. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998;396:670-674 (Pubitemid 29003944)
103. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286 (Pubitemid 129515542)
104. Szekeres PG, Muir AI, Spinage LD, Miller JE, Butler SI, Smith A, et al. Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3. J Biol Chem 2000;275:20247-20250 (Pubitemid 30457595)
105. Kojima M, Haruno R, Nakazato M, Date Y, Murakami N, Hanada R, et al. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem Biophys Res Commun 2000;276:435-438 (Pubitemid 30750937)
106. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411:613-617 (Pubitemid 32531412)
107. Funes S, Hedrick JA, Vassileva G, Markowitz L, Abbondanzo S, Golovko A, et al. The KiSS-1 receptor GPR54 is essential for the development of themurine reproductive system. Biochem Biophys Res Commun 2003;312:1357-1363 (Pubitemid 37490966)
108. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002;8:913-917 (Pubitemid 35033682)
109. Cheng MY, Bullock CM, Li C, Lee AG, Bermak JC, Belluzzi J, et al. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002;417:405-410 (Pubitemid 34563527)
110. Shimomura Y, Harada M, Goto M, Sugo T, Matsumoto Y, Abe M, et al. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem 2002;277:35826-35832
111. Tanaka H, Yoshida T, Miyamoto N, Motoike T, Kurosu H, Shibata K, et al. Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. Proc. Natl Acad Sci USA 2003;100:6251-6256 (Pubitemid 36576962)
112. Liu C, Chen J, Sutton S, Roland B, Kuei C, Farmer N, et al. Identification of relaxin-3/INSL7 as a ligand for GPCR142. J Biol Chem 2003;278:50765-50770
113. Liu C, Eriste E, Sutton S, Chen J, Roland B, Kuei C, et al. Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135. J Biol Chem 2003;278:50754-50764 (Pubitemid 37548924)
114. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004;429:188-193 (Pubitemid 38656195)
115. Cherezov V, Rosenbaum DM, Hason MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007;318:1258-1264 (Pubitemid 350172884)
116. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al. Crystal structure of the human beta2 adrenergic G-Protein-Coupled Receptor. Nature 2007;450:383-387
117. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, et al. A specific cholesterol binding site is established by the 2.8 A structure oh the human beta(2)-adrenergic receptor. Structure 2008;16:897-905.
118. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal stricture of a human A2A adenosine receptor bound to an antagonist. Sicience 2008, 322:1211-1217
119. Warne A, Serrano-Vega MJ, Baker R, Moukhametzianov R, Edwards PC, Henderson R, et al. Structure of the beta1-adrenergic G protein coupled receptor. Nature 2008;454:486-491